What Should Investors Do With the New Wave of IPOs?

Monday.com reported Q1 revenue of $351 million, up 24% year over year, and adjusted EPS of $1.15 versus $0.93 expected, while raising 2026 revenue guidance to about $1.5 billion. Cerebras also boosted its IPO range, targeting a roughly $50 billion valuation and nearly $5 billion in proceeds, but the discussion highlighted heavy customer concentration and a rich valuation near 100x sales. Overall, the segment was constructive on Monday.com's quarter but cautious on Cerebras and the broader IPO backdrop.

Analysis

The key takeaway is not that monday.com suddenly became cheap; it’s that the market had priced in a much worse AI displacement curve than the numbers imply. The hidden positive is that its installed base is still monetizing better than expected, which suggests the threat is less “replacement” and more “feature commoditization” — a slower-burn margin and multiple headwind rather than an abrupt demand collapse. That argues for a trading floor in the stock over the next 1-2 quarters, but not a clean re-rating until management proves the AI layer is incremental rather than defensive.

The more important second-order effect is competitive pressure on the long tail of workflow software. If monday.com can preserve net retention while layering AI credits onto existing accounts, smaller project-management and low-code vendors will likely be forced into either price cuts or heavier R&D spend, which compresses their own margins before they can show AI monetization. Conversely, large platform vendors with adjacent suites — especially AMZN through AWS distribution and embedded enterprise workflows — get a chance to bundle AI ops tools into broader cloud contracts, which is a more efficient go-to-market than standalone SaaS.

Cerebras is a classic pre-IPO sentiment trap: the technology case is real, but the valuation is already discounting a near-perfect path to broad adoption. The real risk is not that the product is useless; it’s that hyperscalers will treat it as a tactical procurement hedge rather than a strategic standard, which caps volumes and makes customer concentration even more dangerous. In that setup, the first-year catalyst is not revenue growth alone but proof that new enterprise wins convert into diversified, repeatable backlog without margin dilution.

The contrarian view is that the market may be underestimating how quickly AI infrastructure winners can become “good enough” rather than dominant. That favors owning the picks-and-shovels with the strongest balance sheets and distribution while shorting or avoiding the most hyped point solutions and first-day IPO exposure. The broader IPO wave is also a liquidity event: capital rotation into marquee names can pressure second-tier software names for weeks, creating better entry points after the initial offering-day euphoria fades.

Key Decisions for Investors

• MNDY: Trade long only on pullbacks, not strength; use the next 4-8 weeks to accumulate only if the stock gives back a meaningful part of the post-earnings gap. Risk/reward improves if the market remains focused on margin expansion rather than deceleration.
• MNDY vs. smaller workflow SaaS: consider a relative-value long MNDY / short weaker AI-exposed workflow names basket for 1-3 months. Thesis is that the strongest incumbent can monetize AI while weaker peers absorb the margin pressure first.
• Avoid day-one Cerebras exposure; if you want optionality, wait 3-6 months for post-IPO price discovery. The setup is asymmetrically bad at the expected valuation because execution needs to be flawless and customer concentration is still a real overhang.
• If buying AI infrastructure exposure, prefer diversified platform winners over niche hardware challengers; AMZN is the cleaner expression if you want AI monetization with distribution and cash-flow support. The risk/reward is better than paying peak multiple for a concentrated IPO story.
• For investors tempted to fund IPOs by trimming winners, do not rotate out of high-quality compounders unless they are demonstrably overvalued and the tax cost is manageable. Use fresh capital or staged entries; the better trade is usually waiting for the new issue to come to you.